Daily Newsletter

30 August 2023

Share with colleague
Subscribe

Daily Newsletter

30 August 2023

Share with colleague
Subscribe

Spotlight

US announces first ten drugs up for Medicare price negotiation

Despite Big Pharma's pushback, plans for Medicare to negotiate prices for blockbuster drugs are going ahead with the release of a new list.

Latest news

Q&A: How the Henrietta Lacks settlement challenges biotech’s view on ethics

Bioethicist Robert Klitzman talks about the Henrietta Lacks lawsuits and the consequences such cases can have for the biotech industry.

30 August 2023

Novartis shows up to 50% cholesterol reduction with Leqvio over six years

Data from the open-label Phase III extension study showed LDL-C levels reduced by half in 80% of the patients receiving twice-yearly treatment of Leqvio.

30 August 2023

Roche’s Evrysdi secures EC approval for spinal muscular atrophy in infants

The approval from the European Commission builds on the FDA's approval for usage in patients aged two months and younger.

30 August 2023

EC grants approval to Merck’s Keytruda for gastric cancer

The regulator approved the treatment based on the findings from the Phase III KEYNOTE-811 trial.

30 August 2023

FDA grants priority review for Zealand Pharma’s dasiglucagon

A decision on the approval from the regulatory agency is anticipated on 30 December 2023.

30 August 2023

Health Canada accepts Valneva’s chikungunya vaccine filing for review

The announcement follows the release of safety data from a Phase III trial in adolescents, which will be used in other submissions.

30 August 2023

Biostax and Immgenuity to expedite HIV immunotherapies development

The companies will determine if the immune-modulatory effects of the combined therapies can achieve remission in HIV patients.

30 August 2023

mRNA vaccines represent >40% of the authorized/approved COVID-19 vaccines and boosters in the 7 major pharmaceutical markets

There are currently 13 authorized/approved COVID-19 vaccines in the 7 major pharma markets. Currently, vaccine developers plan to launch updated boosters prior to the upcoming 2023 fall season to target the latest dominant strain, Omicron XBB.1.5. Per GlobalData analysis, mRNA vaccines will likely continue to dominate the market, though as the pandemic winds down, the global COVID-19 vaccines market is expected to decline.